Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport OLE in pediatric lower limb spasticity
NCT01251380Phase 3Completed
- Sponsor
- Ipsen
- Start
- Oct 2011
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of abobotulinumtoxinA in Spasticity, sponsored by Ipsen. Started Oct 2011; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT01251380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251380.